The discovery that a single metabolic molecule controls the inflammatory cascade of aging could reshape how we understand why cellular damage accelerates in later life. This finding suggests that metabolic health and immune aging are more directly connected than previously recognized, offering potential therapeutic targets for age-related inflammation.
Song and colleagues identified phosphoenolpyruvate (PEP), a key intermediate in glucose metabolism, as a direct inhibitor of cyclic GMP-AMP synthase (cGAS), the cellular sensor that triggers inflammatory responses to DNA damage. The research reveals that PEP levels follow a distinctive biphasic pattern during aging—initially rising as a protective mechanism, then eventually collapsing, which unleashes the chronic inflammation characteristic of advanced age. This metabolic brake system explains why inflammaging and neurodegeneration often emerge suddenly rather than gradually.
This mechanism bridges two fundamental aging theories: metabolic decline and chronic inflammation. The cGAS pathway has emerged as a central driver of age-related pathology, detecting cellular debris and damaged DNA to trigger inflammatory responses. However, the metabolic regulation of this system was poorly understood. The identification of PEP as an endogenous cGAS inhibitor suggests that maintaining glycolytic capacity could be more critical for healthy aging than previously appreciated. The biphasic nature of PEP regulation also explains why some individuals experience relatively stable health until a tipping point where multiple age-related conditions emerge simultaneously. While this single study requires replication across diverse populations, it represents a potentially paradigm-shifting finding that could guide interventions targeting both metabolic health and inflammatory aging through a unified mechanism.
